GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Clinical Trials
3.8k
Trial Phases
5 Phases
Drug Approvals
126
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 13
- Next
Clinical Trials
Distribution across different clinical trial phases (3337 trials with phase data)β’ Click on a phase to view related trials
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-10-27
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1200
- Registration Number
- NCT07221227
- Locations
- πΊπΈ
GSK Investigational Site, Miami, Florida, United States
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-10-27
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1250
- Registration Number
- NCT07221188
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: Placebo
- First Posted Date
- 2025-10-23
- Last Posted Date
- 2025-10-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 750
- Registration Number
- NCT07220109
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
- Conditions
- Gastrointestinal Neoplasms
- Interventions
- First Posted Date
- 2025-10-21
- Last Posted Date
- 2025-10-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 450
- Registration Number
- NCT07218926
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-10-15
- Last Posted Date
- 2025-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT07217119
- Locations
- πΈπͺ
GSK Investigational Site, Stockholm, Sweden
- Prev
- 1
- 2
- 3
- 4
- 5
- 714
- Next
News
GSK Secures $745M License Deal for Novel COPD siRNA Therapy, Receives Orphan Drug Status for Cancer ADC
GSK entered a worldwide exclusive license agreement with Empirico for EMP-012, a first-in-class siRNA targeting a novel therapeutic pathway for COPD treatment, with potential expansion to other inflammatory respiratory diseases.
GSK Acquires Exclusive Rights to Syndivia's Preclinical ADC for Metastatic Castration-Resistant Prostate Cancer
GSK has secured exclusive worldwide rights to develop and commercialize a preclinical antibody-drug conjugate from Syndivia targeting metastatic castration-resistant prostate cancer, with potential payments up to Β£268 million.
GSK's Next-Generation Low-Carbon Ventolin Inhaler Shows Therapeutic Equivalence in Phase III Trial
GSK announced positive phase III data demonstrating therapeutic equivalence and comparable safety between its next-generation low-carbon Ventolin (salbutamol) inhaler using HFA-152a propellant and the current HFA-134a formulation.
Alector's Latozinemab Fails Phase III Trial for Frontotemporal Dementia, Company Cuts Workforce by Half
Alector's investigational antibody latozinemab failed to slow disease progression in a 96-week Phase III trial for frontotemporal dementia caused by progranulin gene mutations.
Dovato Demonstrates Non-Inferior Efficacy to Biktarvy with Significantly Less Weight Gain in 96-Week HIV Treatment Study
ViiV Healthcare's PASO DOBLE trial shows Dovato (DTG/3TC) maintains viral suppression as effectively as Biktarvy (BIC/FTC/TAF) at 96 weeks in 553 virologically suppressed HIV-1 patients.
NICE Approves Long-Acting HIV Prevention Injection for England and Wales
The National Institute for Health and Care Excellence (NICE) has recommended cabotegravir long-acting injection for HIV prevention in England and Wales, offering an alternative to daily oral PrEP for high-risk individuals who cannot take oral medications.
Activist Investor Shah Capital Calls for Novavax Sale Amid COVID Vaccine Market Share Struggles
Shah Capital, Novavax's second-largest shareholder with a 7.2% stake, has urged the company's board to pursue a sale, citing three consecutive years of poor COVID-19 vaccine performance.
Clover Biopharmaceuticals Reports Positive Phase I Data for First-in-Class RSV-hMPV-PIV3 Combination Vaccines
Clover's combination vaccines SCB-1022 and SCB-1033 demonstrated robust immune responses with 6-8 fold increases in RSV neutralizing antibodies, 6-9 fold increases for hMPV, and 4 fold increases for PIV3 in older adults.
New Report Analyzes 1,775 Clinical-Stage Pharma Partnerships from 2020-2025
ResearchAndMarkets.com released a comprehensive report analyzing 1,775 clinical-stage partnering deals in pharma and biotech from 2020-2025, providing detailed financial terms and strategic insights.
GC Biopharma Partners with Curevo Vaccine to Manufacture Next-Generation Shingles Vaccine with Improved Tolerability
GC Biopharma has secured contract manufacturing rights for amezosvatein (CRV-101), a recombinant shingles vaccine designed to reduce injection-site pain and systemic reactions compared to current market leader Shingrix.